Therapeutics
|
OPPORTUNITY NUMBER |
OPPORTUNITY TITLE |
AGENCY NAME |
POSTED DATE |
CLOSE DATE |
|---|---|---|---|---|
| RFA-DA-25-022 | Advancing Technologies to Improve Delivery of Pharmacological, Gene Editing, and other Cargoes for HIV and SUD Mechanistic or Therapeutic Research (R01 Clinical Trial Optional) | HHS-NIH11 | 11/01/2023 | 11/15/2024 |
| RFA-AI-23-054 | Fc-Dependent Mechanisms of Antibody-Mediated Killing (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 09/26/2023 | 01/26/2024 |
| RFA-DA-25-017 | Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 09/21/2023 | 08/13/2024 |
| RFA-DA-25-016 | Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 09/21/2023 | 08/13/2024 |
| PAR-23-238 | Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional) | HHS-NIH11 | 07/19/2023 | 09/07/2026 |
| PAR-23-239 | Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional) | HHS-NIH11 | 07/19/2023 | 09/07/2026 |
| RFA-AT-24-005 | Research Resource for Systematic Reviews of Complementary and Integrative Health (R24 Clinical Trial Not Allowed) | HHS-NIH11 | 07/13/2023 | 08/31/2023 |
| RFA-TR-23-016 | Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 07/05/2023 | 06/02/2025 |
| PAR-24-025 | Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 06/30/2023 | 09/07/2026 |
| PAR-24-024 | Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 06/30/2023 | 09/07/2026 |
| PAR-23-200 | NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed) | HHS-NIH11 | 06/27/2023 | 03/16/2025 |
| PAR-23-205 | NEI Translational Research Program for Therapeutics (R33 Clinical Trial Not Allowed) | HHS-NIH11 | 06/27/2023 | 03/16/2025 |
| PAR-24-210 | Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers (P50 Clinical Trial Optional) | HHS-NIH11 | 06/20/2023 | 05/18/2026 |
| PAR-23-193 | Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed) | HHS-NIH11 | 05/19/2023 | 04/03/2026 |
| PAR-23-177 | Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed) | HHS-NIH11 | 05/11/2023 | 06/19/2025 |
| PAR-23-191 | HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional) | HHS-NIH11 | 05/10/2023 | 12/08/2025 |
| RFA-NS-23-028 | HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional) | HHS-NIH11 | 04/27/2023 | 06/09/2025 |
| PAR-23-160 | Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed) | HHS-NIH11 | 04/13/2023 | 10/17/2024 |
| PAR-23-159 | Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 04/13/2023 | 10/17/2024 |
| PAR-23-105 | Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) | HHS-NIH11 | 01/13/2023 | 05/07/2025 |
| PAR-23-091 | Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 01/06/2023 | 09/07/2025 |
| PAR-23-065 | NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed) | HHS-NIH11 | 11/23/2022 | 01/07/2026 |
| PAR-23-041 | Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed) | HHS-NIH11 | 11/01/2022 | 07/28/2025 |
| RFA-NS-22-070 | HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain(R01 Clinical Trial Not Allowed) | HHS-NIH11 | 08/09/2022 | 03/06/2024 |
| RFA-NS-23-003 | HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional) | HHS-NIH11 | 08/01/2022 | 06/09/2025 |
| PAR-22-216 | NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | HHS-NIH11 | 07/14/2022 | 07/01/2025 |
| PAR-22-189 | Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required) | HHS-NIH11 | 07/12/2022 | 09/11/2025 |
| PAR-22-170 | Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 07/07/2022 | 09/07/2025 |
| PAR-22-185 | Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed) | HHS-NIH11 | 05/27/2022 | 01/17/2025 |
| RFA-OD-22-007 | INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Trial Readiness (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 04/05/2022 | 07/01/2024 |
| PAR-22-139 | Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 03/18/2022 | 05/07/2025 |
| PAR-22-086 | Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 02/18/2022 | 05/07/2025 |
| PAR-22-085 | Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 02/18/2022 | 05/07/2025 |
| PAR-22-111 | Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 02/04/2022 | 01/07/2025 |
| PAR-22-100 | Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed) | HHS-NIH11 | 02/03/2022 | 10/17/2024 |
| PAR-22-101 | Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 02/03/2022 | 10/17/2024 |
| PAR-22-082 | Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) | HHS-NIH11 | 02/03/2022 | 05/07/2025 |
| RFA-HL-23-010 | Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed) | HHS-NIH11 | 01/24/2022 | 12/20/2024 |
| RFA-HL-23-011 | Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed) | HHS-NIH11 | 01/24/2022 | 12/20/2024 |
| RFA-HL-23-012 | Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed) | HHS-NIH11 | 01/24/2022 | 12/20/2024 |
| RFA-NS-22-034 | HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 01/07/2022 | 12/06/2024 |
| PAR-22-031 | Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed) | HHS-NIH11 | 11/29/2021 | 01/07/2025 |
| PAR-22-071 | Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 11/23/2021 | 11/17/2024 |
| PAR-22-032 | Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed) | HHS-NIH11 | 11/17/2021 | 01/07/2025 |
| PAR-22-028 | Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed) | HHS-NIH11 | 11/09/2021 | 09/30/2024 |
| PAR-21-355 | Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional) | HHS-NIH11 | 11/09/2021 | 11/16/2024 |
| PAR-21-354 | Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R03 - Clinical Trial Optional) | HHS-NIH11 | 11/09/2021 | 11/16/2024 |
| PAR-21-353 | Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional) | HHS-NIH11 | 11/09/2021 | 11/05/2024 |
| PAR-21-329 | Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) | HHS-NIH11 | 09/22/2021 | 11/05/2024 |
| PAR-21-338 | Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed) | HHS-NIH11 | 09/22/2021 | 09/13/2024 |
| PAR-21-240 | Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required) | HHS-NIH11 | 06/14/2021 | 03/11/2024 |
| PAR-21-241 | NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required) | HHS-NIH11 | 06/14/2021 | 03/11/2024 |
| PAR-21-211 | Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 Clinical Trial Required) | HHS-NIH11 | 04/01/2021 | 03/16/2024 |
| PAR-21-210 | Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required) | HHS-NIH11 | 04/01/2021 | 03/05/2024 |
| PAR-21-123 | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) | HHS-NIH11 | 03/11/2021 | 02/20/2024 |
| PAR-21-124 | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) | HHS-NIH11 | 03/11/2021 | 02/20/2024 |
| PAR-21-122 | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) | HHS-NIH11 | 03/11/2021 | 02/20/2024 |
| PAR-21-131 | Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required) | HHS-NIH11 | 03/02/2021 | 02/15/2024 |
| PAR-21-135 | Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required) | HHS-NIH11 | 03/02/2021 | 02/15/2024 |
| PAR-21-129 | Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required) | HHS-NIH11 | 03/02/2021 | 02/15/2024 |
| PAR-21-130 | Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required) | HHS-NIH11 | 03/02/2021 | 02/15/2024 |
| PAR-21-137 | Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required) | HHS-NIH11 | 03/02/2021 | 02/15/2024 |
| PAR-21-136 | Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required) | HHS-NIH11 | 03/02/2021 | 02/15/2024 |
| PAR-21-134 | Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required) | HHS-NIH11 | 03/02/2021 | 02/15/2024 |
| PAR-21-132 | Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required) | HHS-NIH11 | 03/02/2021 | 02/15/2024 |
| PAR-21-033 | National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | HHS-NIH11 | 11/12/2020 | 01/07/2024 |